131 related articles for article (PubMed ID: 9323150)
1. Localization of plasminogen activators and their inhibitor in squamous cell carcinomas of the head and neck.
Yasuda T; Sakata Y; Kitamura K; Morita M; Ishida T
Head Neck; 1997 Oct; 19(7):611-6. PubMed ID: 9323150
[TBL] [Abstract][Full Text] [Related]
2. [Immunohistological study of fibrinolytic factors of head and neck squamous cell carcinomas].
Itaya T; Motai H; Suzuki K; Baba S
Nihon Jibiinkoka Gakkai Kaiho; 1995 Feb; 98(2):197-202. PubMed ID: 7707177
[TBL] [Abstract][Full Text] [Related]
3. Transforming growth factor beta1, urokinase-type plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in head and neck squamous carcinoma and normal adjacent mucosa.
Pasini FS; Brentani MM; Kowalski LP; Federico MH
Head Neck; 2001 Sep; 23(9):725-32. PubMed ID: 11505481
[TBL] [Abstract][Full Text] [Related]
4. Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) in tissue and serum of head and neck squamous cell carcinoma patients.
Strojan P; Budihna M; Smid L; Vrhovec I; Skrk J
Eur J Cancer; 1998 Jul; 34(8):1193-7. PubMed ID: 9849478
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and alpha(2)-macroglobulin receptor in human breast carcinomas.
Christensen L; Wiborg Simonsen AC; Heegaard CW; Moestrup SK; Andersen JA; Andreasen PA
Int J Cancer; 1996 May; 66(4):441-52. PubMed ID: 8635858
[TBL] [Abstract][Full Text] [Related]
6. Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination.
Nagayama M; Sato A; Hayakawa H; Urano T; Takada Y; Takada A
Cancer; 1994 Mar; 73(5):1398-405. PubMed ID: 8111706
[TBL] [Abstract][Full Text] [Related]
7. Keratinocytes and head and neck squamous cell carcinoma cells regulate urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in fibroblasts.
Hakelius M; Koskela A; Ivarsson M; Grenman R; Rubin K; Gerdin B; Nowinski D
Anticancer Res; 2013 Aug; 33(8):3113-8. PubMed ID: 23898067
[TBL] [Abstract][Full Text] [Related]
8. In vitro urokinase type plasminogen activator levels and total plasminogen activator activity in squamous cell carcinomas of the head and neck.
Petruzzelli GJ; Snyderman CH; Johnson JT
Arch Otolaryngol Head Neck Surg; 1994 Sep; 120(9):989-92. PubMed ID: 8074827
[TBL] [Abstract][Full Text] [Related]
9. Expression of plasminogen activators and plasminogen activator inhibitor 1 in dedifferentiated chondrosarcoma.
Häckel C; Czerniak B; Ayala AG; Radig K; Roessner A
Cancer; 1997 Jan; 79(1):53-8. PubMed ID: 8988726
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical study of tumor cell-associated plasminogen activators and plasminogen activator inhibitors in lung carcinomas.
Gris JC; Schved JF; Marty-Double C; Mauboussin JM; Balmes P
Chest; 1993 Jul; 104(1):8-13. PubMed ID: 7686838
[TBL] [Abstract][Full Text] [Related]
11. Production of urokinase-type plasminogen activator (u-PA) and plasminogen activator inhibitor-1 (PAI-1) in human brain tumours.
Arai Y; Kubota T; Nakagawa T; Kabuto M; Sato K; Kobayashi H
Acta Neurochir (Wien); 1998; 140(4):377-85; discussion 385-6. PubMed ID: 9689330
[TBL] [Abstract][Full Text] [Related]
12. [Expression and significance of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx].
Zhao EM; Han DM; Yu ZK; Fan EZ; Li Y
Zhonghua Er Bi Yan Hou Ke Za Zhi; 2003 Feb; 38(1):39-42. PubMed ID: 12778766
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical demonstration of the plasminogen activator system in human gingival tissues and gingival fibroblasts.
Xiao Y; Bunn CL; Bartold PM
J Periodontal Res; 1998 Jan; 33(1):17-26. PubMed ID: 9524317
[TBL] [Abstract][Full Text] [Related]
14. [Comparison of urokinase type plasminogen activators (uPA) and plasminogen activator inhibitors (PAI-1) in primary resection of oral squamous cell carcinoma].
Hundsdorfer B; Zeilhofer HF; Bock KP; Dettmar P; Schmitt M; Horch HH
Mund Kiefer Gesichtschir; 2004 May; 8(3):180-90. PubMed ID: 15138856
[TBL] [Abstract][Full Text] [Related]
15. Expression of plasminogen activators and plasminogen activator inhibitors in cutaneous melanomas of transgenic melanoma-susceptible mice.
de Vries TJ; Kitson JL; Silvers WK; Mintz B
Cancer Res; 1995 Oct; 55(20):4681-7. PubMed ID: 7553649
[TBL] [Abstract][Full Text] [Related]
16. [Tissue and urokinase plasminogen activators (t-PA, u-PA) and their inhibitor PAI-1 in blood of patients with laryngeal neoplasms].
Białkowska A; Kotschy M; Betlejewski S; Burduk D
Otolaryngol Pol; 1995; 49 Suppl 20():84-7. PubMed ID: 9454229
[TBL] [Abstract][Full Text] [Related]
17. [The location of components of fibrinolytic system in laryngeal cancer].
Sierko E; Tokajuk P; Zimnoch L; Wojtukiewicz MZ
Pol Merkur Lekarski; 2003 Jul; 15(85):81-5. PubMed ID: 14593967
[TBL] [Abstract][Full Text] [Related]
18. Distinct encounter complexes of PAI-1 with plasminogen activators and vitronectin revealed by changes in the conformation and dynamics of the reactive center loop.
Qureshi T; Goswami S; McClintock CS; Ramsey MT; Peterson CB
Protein Sci; 2016 Feb; 25(2):499-510. PubMed ID: 26548921
[TBL] [Abstract][Full Text] [Related]
19. Quantitative evaluation of the influence of ovarian steroids on plasminogen activators and inhibitors in human endometrial cells and trophoblasts.
Ueyama M; Kasatori N; Urayama T; Maemura T; Yao Y; Shiraishi T; Saito S; Kubo H
Thromb Res; 2002 Nov; 108(4):235-44. PubMed ID: 12617987
[TBL] [Abstract][Full Text] [Related]
20. Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma.
Shiomi H; Eguchi Y; Tani T; Kodama M; Hattori T
Am J Pathol; 2000 Feb; 156(2):567-75. PubMed ID: 10666386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]